This information is disseminated under the sponsorship of the U.S. Department of Transportation
in the interest of information exchange.
The United States Government assumes no Liability for the contents or use thereof.
Rizatriptan |
| Description |
Rizatriptan (trade name Maxalt) is a 5-HT1 agonist triptan drug developed by Merck & Co. for the treatment of migraine headaches. |
| Therapeutic Low |
0.0150 |
| Therapeutic High |
0.0770 |
| Units |
ug/mL |
| Specimen |
P |
| Half Life Low |
2.00 |
| Half Life High |
3.00 |
| VOD Low |
1.30 |
| VOD High |
2.20 |
| Toxic Level |
0.000 |
| Lethal Level |
0.000 |
| Plasma to Whole Blood ratio |
0.00 |
| Warnings |
Side effects include increased risk of cardiac ischemia and serotonin syndrome. |